Tag: hereditary angioedema therapeutics market analysis

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Hereditary Angioedema Therapeutics Industry?

The market size of therapeutics for hereditary angioedema has seen a swift increase in the recent past. It is expected to enlarge from $6.68 billion in 2024 to $7.77 billion in 2025, witnessing a compound annual growth rate (CAGR) of 16.3%. The remarkable growth during the historical phase can be credited to factors such as enhanced diagnosis and awareness, extended accessibility of treatments, research and development efforts, as well as initiatives for patient advocacy and education, and regulatory endorsements.

Expectations are high for the hereditary angioedema therapeutics market, with rapid growth anticipated in the coming years. Its projected size by 2029 is an impressive $15.84 billion, reflecting a compound annual growth rate (CAGR) of 19.5%. This predicted growth within the forecast period is mainly due to key developments such as targeted therapies, market globalization, breakthroughs in gene therapy, advancements in personalized medicine, and research and treatment collaborations. The forecast period also carries important trends including initiatives for global access, health economic outcomes research, strategies for early intervention, and therapeutics for pediatric HAE.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Forces Are Driving The Growth Of The Hereditary Angioedema Therapeutics Industry?

The increasing incidence of hereditary angioedema is projected to boost the progression of the hereditary angioedema market. Hereditary angioedema (HAE) is an uncommon genetic ailment, marked by frequent bouts of severe swelling of the skin and mucous membranes due to an excessive accumulation of fluid (EDEMA). This swelling can transpire anywhere in the body such as the hands, feet, face, intestines and airways. For example, as reported by Rare Disease Advisor, a digital resource platform catering to global healthcare professionals, in June 2022, hereditary angioedema affects roughly 1 in 50,000 individuals worldwide, with prevalence estimates varying between 1:10,000 to 1:150,000. The disease is responsible for 15,000 to 30,000 emergency room visits annually in the United States. Here 5.8% of HAE cases had an average diagnosis time duration between 0 to 6 months, while another 5.8% took over 10 years for diagnosis. As a result, this escalating occurrence of hereditary angioedema is steering the hereditary angioedema market’s expansion.

What Is The Overview Of Market Segmentation In The Hereditary Angioedema Therapeutics Industry?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Future Market Trends Are Projected For The Hereditary Angioedema Therapeutics Industry?

Leading product innovations are emerging as a pivotal trend in the hereditary angioedema therapeutics market. Major corporations in this area are focusing on creating ground-breaking products including ligand-conjugated (LICA) experimental antisense drugs and gene therapy to maintain their dominance. For instance, in March 2023, US-based clinical-stage biotech firm Intellia Therapeutics launched a new investigational drug, NTLA-2002, approved by the US Food and Drug Administration for treating hereditary angioedema. This approval expands the company’s ongoing Phase 1/2 trial to incorporate the US into the global Phase 2 section. Upon a single-dose administration, the target gene, Kallikrein B1 (KLKB1), is permanently inactivated, reducing plasma kallikrein protein activity and preventing HAE attacks. NTLA-2002 stands as a contender for in vivo genome editing.

Who Are The Primary Players Operating Across The Global Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Region Offers The Most Growth Potential For The Hereditary Angioedema Therapeutics Market Through 2029?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Hereditary Angioedema Therapeutics Market Growth in 2025?

The market size for hereditary angioedema therapeutics has seen substantial growth in the past few years. It’s projected to expand from a valuation of $6.68 billion in 2024 to $7.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.3%. This significant growth during the historic period can be attributed to various factors such as enhanced diagnosis and awareness, the expansion of treatment accessibility, initiatives in research and development, efforts in patient advocacy and education, and successful regulatory approvals.

What Is the Forecast for the Hereditary Angioedema Therapeutics Market Size Through 2029?

Expectations are high for the hereditary angioedema therapeutics market, as its fast-paced expansion is predicted in the coming years. The market is set to reach a valuation of $16.11 billion by 2029, with a 19.7% compound annual growth rate. This predicted growth during the forecast period can be credited to advancements in targeted therapies, global market expansion, gene therapy developments, the trend towards personalized medicine, and increased collaboration in research and treatment. The forecast period will also witness trends such as global access initiatives, health economic outcomes research, early intervention strategies, and an increase in pediatric HAE therapeutics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What are the Key Market Players in Hereditary Angioedema Therapeutics Market and How They’re Evolving?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Hereditary Angioedema Therapeutics Market?

The hereditary angioedema market is likely to witness growth driven by the increasing rate of hereditary angioedema. This rare genetic disorder, known as Hereditary Angioedema or HAE, results in recurrent bouts of severe skin and mucous membrane swelling. The cause for such swelling is typically excess fluid accumulation or edema and can manifest in different areas of the body like hands, feet, face, intestines, and airways. To give an example, in June 2022, data from Rare Disease Advisor, a globally reaching online health care information provider, stated that hereditary angioedema affects 1 in every 50,000 people. The prevalence ranges between 1 in 10,000 to 1 in 150,000. Each year in the US, HAE episodes lead to between 15,000-30,000 ER visits. 5.8% of HAE cases are diagnosed within a 0-6 month period, while for another 5.8%, diagnosis took over 10 years. These rising instances of hereditary angioedema are thus contributing to the growth of the hereditary angioedema market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

What Are the Leading Segments in the Global Hereditary Angioedema Therapeutics Industry?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Are the Key Market Trends in the Hereditary Angioedema Therapeutics Industry?

The emergence of product innovations is a prominent trend that is particularly noticeable in the hereditary angioedema therapeutics market. Industry leaders are manufacturing inventive products like gene therapy and ligand-conjugated (LICA) investigational antisense medication to maintain their status within the market. For instance, in March 2023, the USA-based biotech firm Intellia Therapeutics introduced an Investigational New Drug (IND) named NTLA-2002. The United States Food and Drug Administration gave its stamp of approval for this drug to be used in the treatment of hereditary angioedema. This approval allows the firm to broaden the scope of its ongoing Phase 1/2 trial to incorporate the United States into the Phase 2 part on a global scale. After a single dose, the therapy will permanently disable the kallikrein B1 (KLKB1) target gene, thereby substantially reducing the activity of the plasma kallikrein protein and eradicating HAE attacks. NTLA-2002 is posed to play a crucial role in in vivo genome editing.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

What Is the Regional Outlook for the Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

This Report Delivers Insight On:

1. How big is the hereditary angioedema therapeutics market, and how is it changing globally?

2. Who are the major companies in the hereditary angioedema therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the hereditary angioedema therapeutics market right now?

4. Which products or customer segments are growing the most in the hereditary angioedema therapeutics market?

5. What factors are helping or slowing down the growth of the hereditary angioedema therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theHereditary Angioedema Therapeutics Market?

The increasing incidence of hereditary angioedema is anticipated to spur the expansion of the hereditary angioedema market in the future. Hereditary angioedema (HAE) is an uncommon genetic condition that is defined by frequent bouts of serious swelling of the skin and mucous membranes. This swelling is due to an excessive build-up of fluid (EDEMA) and can happen anywhere in the body, such as the hands and feet, face, intestines, and airways. For instance, in June 2022, Rare Disease Advisor, a digital health resource company, reported that globally, 1 in every 50,000 individuals is affected by hereditary angioedema, with prevalence estimates ranging from 1:10,000 to 1:150,000. Annually in the US, HAE episodes result in 15,000 to 30,000 emergency room visits. 5.8% of hereditary angioedema cases had an average diagnostic time of 0 to 6 months, and another 5.8% had an average diagnostic time of over 10 years. Therefore, the escalating incidence of hereditary angioedema fuels the growth of the hereditary angioedema market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What is the Predicted Annual Growth Rate of theHereditary Angioedema Therapeutics Market Impact Industry Trends by 2034?

The market size for hereditary angioedema therapeutics has seen a significant expansion in the recent past. It is projected to increase from $6.68 billion in 2024 to $7.84 billion in 2025, registering an impressive compound annual growth rate (CAGR) of 17.3%. This growth during the historic period is credited to enhanced diagnosis and awareness, broadened access to treatment, initiatives in research and development, patient advocacy and education, and regulatory sanctions.

In the coming years, the market size for therapeutics related to hereditary angioedema is anticipated to witness a swift expansion. The market is projected to reach “$16.11 billion by 2029, growing at a compound annual growth rate (CAGR) of 19.7%. The significant growth during the predicted period can be credited to enhancements in targeted treatments, the worldwide market’s proliferation, breakthroughs in gene therapy, the trend of personalized medicines, and collaborative efforts in research and cure. The forecast period is set to observe major trends like global reach initiatives, research on health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

Which Cutting-Edge Market Trends Are Expected to Drive theHereditary Angioedema Therapeutics Market’s Growth?

Leading companies in the hereditary angioedema therapeutics market are embracing product innovation as a growing trend. These companies, in an attempt to maintain their market standing, are creating cutting-edge products such as ligand-conjugated (LICA) experimental antisense drugs and gene therapy. For instance, Intellia Therapeutics, a clinical-stage biotechnology firm based in the US, launched a groundbreaking Investigational New Drug (IND) NTLA-2002 in March 2023. This drug was sanctioned by the United States Food and Drug Administration for treating hereditary angioedema, allowing the company to include the US in their existing Phase 1/2 trial onto the global Phase 2 part. The goal is to permanently reduce plasma kallikrein protein activity and impede HAE attacks by incapacitating the target gene, kallikrein B1 (KLKB1), with a singular dose of therapy. Thus, NTLA-2002 is poised as a potential candidate for in vivo genome editing.

What Are the Leading Market Players Impacting theHereditary Angioedema Therapeutics Market’s Growth Trend?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

How Are the Key Segments of the Hereditary Angioedema Therapeutics Market Driving Opportunities and Innovations?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theHereditary Angioedema Therapeutics Market?# Market Expansion?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Hereditary Angioedema Therapeutics Maret 2025, By The Business Research Company:

Online Therapy Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/online-therapy-services-global-market-report

Vitamin D Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Targeted Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the hereditary angioedema therapeutics market size evolved in recent years?

The market size for therapeutics dealing with hereditary angioedema has experienced a swift expansion in recent times. The market, which was worth $6.68 billion in 2024, is projected to increase to $7.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.3%. Factors contributing to the growth during the historical period include bettered diagnosis and awareness, broadened access to treatments, research and development projects, patient advocacy and education, and regulatory green signals.

What are the predictions for the hereditary angioedema therapeutics market size in the coming years?

The market for therapeutics related to hereditary angioedema is predicted to surge rapidly in the coming years, growing to “$16.11 billion by 2029 with a compound annual growth rate (CAGR) of 19.7%. The growth for the projected period can be linked to improvements in targeted therapies, the expansion of the global market, progress in gene therapy, the popularity of personalized medicine, and collaborative efforts in research and treatment. Key trends in the projected period encompass global access initiatives, research on health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.

Get your hereditary angioedema therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

What key factors are fueling the growth of the hereditary angioedema therapeutics market?

The increasing incidence of hereditary angioedema is projected to fuel the expansion of the hereditary angioedema market in the future. Hereditary angioedema, or HAE, is a rare inherited condition that is characterised by recurring severe swelling incidents of the skin and mucus membranes, attributable to an accumulation of excess fluid known as edema. This swelling can present itself anywhere on the body, such as the hands, feet, face, intestines, and airways. To illustrate, in June 2022, the online health information provider, Rare Disease Advisor, stated that globally, hereditary angioedema affects one in every 50,000 individuals, with prevalence estimates varying from 1:10,000 to 1:150,000. Each year, HAE episodes result in between 15,000 to 30,000 emergency room visits in the US. In 5.8% of HAE cases, the average diagnosis time span was 0 to 6 months, while in another 5.8% of cases, the diagnosis took over 10 years. Hence, the escalating incidence of hereditary angioedema is pushing the hereditary angioedema market’s growth forward.

How is the global hereditary angioedema therapeutics market divided into key segments?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Who are the key firms paving the way for growth in the hereditary angioedema therapeutics market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Which trends are expected to transform the hereditary angioedema therapeutics market?

A significant trend that is increasingly gaining traction in the hereditary angioedema therapeutics market is the innovation of products. The dominant players in this market are investing in groundbreaking products like ligand-conjugated (LICA) investigational antisense medicine and gene therapy to maintain their market stake. For instance, in March 2023, the US-based clinical-stage biotechnology enterprise, Intellia Therapeutics, introduced Investigational New Drug (IND) NTLA-2002, duly approved by the United States Food and Drug Administration for treating hereditary angioedema. This has allowed the company to extend its ongoing Phase 1/2 trial to cover the US in the worldwide Phase 2 aspect. Upon administering a single dose of therapy, the target gene, kallikrein B1 (KLKB1), will be permanently deactivated, which will decrease plasma kallikrein protein activity and inhibit HAE attacks in the long term. NTLA-2002 is a potential candidate for in vivo genome editing.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

What regions are contributing significantly to the growth of the hereditary angioedema therapeutics market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Online Therapy Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/online-therapy-services-global-market-report

Vitamin D Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Targeted Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Predicted Annual Growth Rate of the Hereditary Angioedema Therapeutics Market Over the Coming Decade?

The market for therapeutics in hereditary angioedema has seen a swift expansion in the recent past. The market is projected to rise from $6.68 billion in 2024 to $7.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 17.3%. The growth experienced in the historic timeframe can be traced back to factors such as increased awareness and diagnosis, widened access to treatments, initiatives in research and development, patient advocacy and education, alongside regulatory authorizations.

The market for hereditary angioedema therapeutics is predicted to experience swift expansion in the coming years, hitting a size of “$16.11 billion in 2029 with an annual compound growth rate (CAGR) of 19.7%. This growth during the forecast period can be tied to the progress in targeted therapies, the broadening of the worldwide market, development of gene therapy, trends in personalized medicine, and collaborations in research and therapies. Some major trends expected during the forecast period include initiatives for global access, research on health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.

What Combination of Drivers Is Leading to Accelerated Growth in the hereditary angioedema therapeutics Market?

The increasing incidence of hereditary angioedema is predicted to lead the hereditary angioedema market towards progression. Hereditary angioedema (HAE), a rare genetic ailment, is marked by consistent episodes of intense swelling in the skin and mucosal areas. This swelling results from excessive accumulation of fluid (EDEMA) and it could manifest anywhere in the body, including hands, feet, face, intestines, and airways. As reported by Rare Disease Advisor, an online resource company providing services to global health care professionals, in June 2022, hereditary angioedema affects 1 out of every 50,000 individuals, with prevalence estimates ranging from 1:10,000 to 1:150,000. In the US, HAE episodes lead to 15,000 to 30,000 ER visits annually. While 5.8% of HAE cases were diagnosed within 0 to 6 months, another 5.8% took over 10 years for diagnosis. Hence, the rise in hereditary angioedema cases contributes to the growth of the hereditary angioedema market.

Explore Comprehensive Insights Into The Global Hereditary Angioedema Therapeutics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Are the Major Players Making an Impact in the Hereditary Angioedema Therapeutics Market’s Growth?

Major companies operating in the hereditary angioedema therapeutics market include:

• Sanofi S.A._x000D_

• Pharming Healthcare Inc._x000D_

• Attune Pharmaceuticals Inc._x000D_

• Adverum Biotechnologies Inc._x000D_

• Arrowhead Pharmaceuticals Inc._x000D_

Which Upcoming Trends Are Set to Influence the Hereditary Angioedema Therapeutics Market’s Path Forward?

Secure Your Global Hereditary Angioedema Therapeutics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Key Segments Define the Structure of the Hereditary Angioedema Therapeutics Market and Their Growth Potential?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Regions Are Steering Growth in the Hereditary Angioedema Therapeutics Sector?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Hereditary Angioedema Therapeutics Market Classified and Defined in Market Analysis?

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.

Browse Through More Similar Reports By The Business Research Company:

Online Therapy Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/online-therapy-services-global-market-report

Vitamin D Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Targeted Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: